Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Zdeněk TrávníčekCzech Advanced Technology and Research Institute, Regional Centre of Advanced Technologies and Materials, Palacký University, Šlechtitelů 27, 77900 Olomouc, Czech Republic.ORCID 0000-0002-5890-7874
Ján VančoCzech Advanced Technology and Research Institute, Regional Centre of Advanced Technologies and Materials, Palacký University, Šlechtitelů 27, 77900 Olomouc, Czech Republic.ORCID 0000-0003-3351-1192
Jan BelzaCzech Advanced Technology and Research Institute, Regional Centre of Advanced Technologies and Materials, Palacký University, Šlechtitelů 27, 77900 Olomouc, Czech Republic.
Jan HošekCzech Advanced Technology and Research Institute, Regional Centre of Advanced Technologies and Materials, Palacký University, Šlechtitelů 27, 77900 Olomouc, Czech Republic.ORCID 0000-0003-0975-1671
Zdeněk DvořákDepartment of Cell Biology and Genetics, Faculty of Science, Palacký University, Šlechtitelů 27, 78371 Olomouc, Czech Republic.ORCID 0000-0002-3938-3585
René LenobelLaboratory of Growth Regulators, Institute of Experimental Botany of the Czech Academy of Sciences, Faculty of Science, Palacký University, Šlechtitelů 27, 78371 Olomouc, Czech Republic.
Igor PopaCzech Advanced Technology and Research Institute, Regional Centre of Advanced Technologies and Materials, Palacký University, Šlechtitelů 27, 77900 Olomouc, Czech Republic.
Karel ŠmejkalDepartment of Natural Drugs, Faculty of Pharmacy, Masaryk University, Palackého tř. 1946/1, 61242 Brno, Czech Republic.ORCID 0000-0002-4336-7924
Pavel UhrinInstitute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstrasse 17, 1090 Vienna, Austria.ORCID 0000-0002-9792-3420
Funding
FWF Austrian Science Fund FWF I 5215Ministry of Education Youth and Sports 21-38204LMinistry of Education Youth and Sports CZ.02.1.01/0.0/0.0/16_019/0000754
6 · The paper itself
Abstract
Motivated by the clinical success of gold(I) metallotherapeutic
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Gold(I) Complex with Plant Hormone Kinetin Shows Promising In Vitro Anticancer and PPARγ Properties. · full record | OpenQuestion